Patrick John Finn Sells 10,340 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 10,340 shares of the firm’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares in the company, valued at $10,610,928. This represents a 4.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Patrick John Finn also recently made the following trade(s):

• On Wednesday, November 6th, Patrick John Finn sold 6,239 shares of Twist Bioscience stock. The stock was sold at an average price of $44.60, for a total transaction of $278,259.40.
• On Monday, November 4th, Patrick John Finn sold 2,681 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total transaction of $111,422.36.
• On Wednesday, October 23rd, Patrick John Finn sold 2,261 shares of Twist Bioscience stock. The stock was sold at an average price of $43.09, for a total transaction of $97,426.49.
• On Wednesday, October 2nd, Patrick John Finn sold 6,865 shares of Twist Bioscience stock. The stock was sold at an average price of $43.21, for a total transaction of $296,636.65.

Twist Bioscience Stock Down 8.3 %

Shares of NASDAQ TWST opened at $38.96 on Friday. Twist Bioscience Co. has a 1-year low of $18.80 and a 1-year high of $60.90. The company has a 50-day moving average of $43.90 and a two-hundred day moving average of $45.88.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Barclays dropped their price objective on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. Finally, Evercore ISI lifted their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $51.22.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently modified their holdings of the business. SageView Advisory Group LLC bought a new stake in shares of Twist Bioscience during the first quarter worth approximately $1,144,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Twist Bioscience during the first quarter worth approximately $300,000. Sei Investments Co. raised its stake in shares of Twist Bioscience by 32.7% during the first quarter. Sei Investments Co. now owns 223,555 shares of the company’s stock worth $7,670,000 after buying an additional 55,124 shares during the last quarter. Silvercrest Asset Management Group LLC raised its stake in shares of Twist Bioscience by 38.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 134,215 shares of the company’s stock worth $4,605,000 after buying an additional 37,376 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.